Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new class of targeted drugs is showing striking results in one of oncology's toughest cancers. INCB161734, a selective KRAS G12D inhibitor, produced response rates as high as 89% when combined with standard chemotherapy in pancreatic ductal adenocarcinoma (PDAC). These results are now powering the phase 3 DAWN-303 trial, which aims to establish this combination as a frontline standard of care for KRAS G12D–mutated PDAC.
A wave of KRAS G12D–targeted therapies is transforming the treatment landscape for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers. INCB161734, a selective oral inhibitor that blocks the KRAS G12D mutation in both its active and inactive states, has demonstrated impressive efficacy in combination with standard chemotherapy regimens — without the skin toxicities seen with broader pan-RAS inhibitors. Its favorable safety profile has enabled a straightforward phase 3 trial design: the DAWN-303 trial, which randomizes previously untreated KRAS G12D–mutated metastatic PDAC patients to chemotherapy with or without INCB161734, with no need for a separate monotherapy arm.
Another KRAS G12D inhibitor, VS-7375, is also showing promise, with a 50% confirmed ORR in second-line PDAC and two complete responses — reinforcing the momentum of this drug class across multiple tumor types.
By the Numbers
Why it matters: KRAS G12D mutations drive roughly 40% of PDAC cases, a disease with historically dismal outcomes. If DAWN-303 succeeds, it could establish the first mutation-specific frontline regimen for this patient population — fundamentally splitting PDAC treatment into KRAS G12D and non-G12D pathways.
